Topical Delgocitinib for Capecitabine-Induced Hand–Foot Syndrome: A Therapeutic Option?
Hand–foot syndrome (HFS) is a frequent and potentially dose-limiting adverse event of capecitabine. Current therapeutic strategies are not always effective. Since inflammatory pathways, including JAK-STAT3 signaling, may contribute to capecitabine-induced HFS, topical JAK inhibition could represent a potential therapeu...